-
PDF
- Split View
-
Views
-
Cite
Cite
Erratum, Clinical Infectious Diseases, Volume 70, Issue 6, 15 March 2020, Page 1265, https://doi.org/10.1093/cid/ciaa060
Close - Share Icon Share
The following error appeared in the corrected proof publication of this article [Shields RK, McCreary EK, Marini RV, et al. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clin Infect Dis https://doi.org/10.1093/cid/ciz1131].
In the first paragraph of the article, it currently states “Meropenem-vaborbactam was associated with fewer severe treatment-emergent adverse events (TEAEs; 17/50 [34%] vs 7/25 [28%]) and renal-related TEAEs (2/50 [4%] vs 6/25 [24%]) than BAT.”
It should correctly state “Meropenem-vaborbactam was associated with fewer severe treatment-emergent adverse events (TEAEs; 7/50 [14%] vs 7/25 [28%]) and renal-related TEAEs (2/50 [4%] vs 6/25 [24%]) than BAT.”
The author regrets this error.
